Detailed answers about SUKOVICH CELLULAR MOLECULAR CONSULTING LIMITED, including incorporation, status, business activity, and accounts information.
When was SUKOVICH CELLULAR MOLECULAR CONSULTING LIMITED founded?
SUKOVICH CELLULAR MOLECULAR CONSULTING LIMITED was officially incorporated on 6 October 2026 and is registered under company number 17502306. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is SUKOVICH CELLULAR MOLECULAR CONSULTING LIMITED?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of SUKOVICH CELLULAR MOLECULAR CONSULTING LIMITED?
SUKOVICH CELLULAR MOLECULAR CONSULTING LIMITED's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does SUKOVICH CELLULAR MOLECULAR CONSULTING LIMITED do?
SUKOVICH CELLULAR MOLECULAR CONSULTING LIMITED operates in the following sector: 70229 - Management consultancy activities other than financial management. This provides insight into the company's primary business activity and industry focus.
What is SUKOVICH CELLULAR MOLECULAR CONSULTING LIMITED's registered address?
The registered office address of SUKOVICH CELLULAR MOLECULAR CONSULTING LIMITED is Chancellors House 3 Brampton Lane, Hendon, London, England, NW4 4AB. This is the official address filed with Companies House for legal and statutory correspondence.
Is SUKOVICH CELLULAR MOLECULAR CONSULTING LIMITED financially stable?
Financial accounts for SUKOVICH CELLULAR MOLECULAR CONSULTING LIMITED are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.